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Background: Cervicomediastinal lymph node carcinoma with an unknown primary site is quite rare, and useful
treatment of these diseases has not been established. We report here the case of a patient successfully treated with
TS-1 alone after the relapse of cervicomediastinal lymph node carcinoma with an unknown primary site.
Case presentation: A 62-year-old man was referred to our hospital because of cervicomediastinal lymph node swelling
and high serum levels of carbohydrate antigen 19-9 and carcinoembryonic antigen. Fluorodeoxyglucose-positron
emission tomography/computed tomography revealed an accumulation of fluorodeoxyglucose in the left
supraclavicular lymph nodes, mediastinal lymph nodes, and the pelvic cavity. Colonoscopy revealed rectal cancer, which
was diagnosed by biopsy as a tubular adenocarcinoma. Because metastases from rectal cancer to the cervicomediastinal
lymph nodes are rare, the patient underwent thoracoscopic mediastinal lymphadenectomy. A biopsy specimen from the
paraaortic lymph nodes demonstrated papillary adenocarcinoma that was pathologically different from the rectal cancer;
therefore, a diagnosis of mediastinal carcinoma with an unknown primary site was established. The patient underwent
low anterior resection of the rectum for the rectal cancer, and no abdominal lymph node metastasis (pMP, N0/stage I)
was found. Although radiotherapy was performed for the cervicomediastinal lymph nodes, the mediastinal carcinoma
relapsed after 6 months. Because the patient desired oral chemotherapy on an outpatient basis, TS-1 was administered
at a dosage of 80 mg/day for 2 weeks, followed by a 1-week rest. TS-1 treatment resulted in a decrease in the size of the
cervicomediastinal lymph nodes, and the serum tumor marker levels decreased to normal after the fourth course. The
patient continued TS-1 treatment without adverse events and is currently alive without recurrence or identification of
the primary site at the 32nd month after TS-1 treatment.
Conclusion: This is the first reported case of relapsed cervicomediastinal lymph node carcinoma with an unknown
primary site treated by TS-1 alone. TS-1 treatment for the carcinoma with an unknown primary site may be useful in
patients who are not candidates for systemic platinum-based chemotherapy.
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Metastatic carcinoma with an unknown primary site
accounts for approximately 2%-10% of all solid malig-
nancies; therefore, it is one of the 10 most frequent
cancer diagnoses worldwide [1-4]. The patients present
with metastatic disease for which a primary site cannot
be detected at the time of diagnosis and have a poor
prognosis (median survival of 6-9 months). Mediastinal* Correspondence: yajimatos@yahoo.co.jp
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reproduction in any medium, provided the orlymph node (LN) carcinoma with an unknown primary
site is rare, accounting for 1.5% of all carcinomas with
an unknown primary site [5]. Several cases have been
reported in which radical excision of the mediastinal
LN carcinoma resulted in a better prognosis than for
the primary lung cancer with mediastinal LN metastasis
[6-8]. In contrast, some cases with multiple mediastinal
LN carcinomas with an unknown primary site, which were
not eligible for radical excision, had a poor prognosis [9].
Although a useful chemotherapy has not been established
for multiple LN carcinomas with an unknown primary
site, platinum-based doublet chemotherapy has often beenLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in Japan consisting of tegafur (a pro-drug of fluorouracil,
5-FU), gimeracil and oteracil potassium and has been
mainly used for treatment of stomach cancer, non-
small-cell lung cancer, colon and rectal cancer, head
and neck cancer, inoperability or recurrence of breast
cancer, and pancreatic cancer [12,13]. We report here the
case of a patient with cervicomediastinal LN carcinoma
with an unknown primary site that had relapsed after
radiotherapy. The carcinoma was improved dramatically
by TS-1 treatment alone.
Case presentation
A 62-year-old man was admitted to our hospital with
hoarseness of voice in November 2008. Computed tom-
ography (CT) revealed enlargement of LNs located at
the left supraculavicular site, the level of Botallo’s liga-
ment, and the left side of the ascending aorta, which
had diameters of 18 mm, 18 mm, and 14 mm, respectively.
The hoarseness was caused by left vocal cord palsy as a
result of the compression of the left recurrent laryngeal
nerve by enlarged Botallo’s LNs. The hematological,
hepatic, and renal function tests were all within the
normal range. The serum levels of carbohydrate antigen
19-9 (CA19-9) and carcinoembryonic antigen (CEA)
were found to be dramatically elevated to 16149.0 U/ml
and 72.7 U/ml, respectively (Figure 1). Fluorodeoxyglucose
(FDG) - positron emission tomography (PET)/CT revealed
an accumulation of FDG in the left supraclavicular LNs,
mediastinal LNs, and the pelvic cavity, with maximum
standardized uptake values of 8.26, 10.44, and 6.43, respect-
ively (Figure 2). Colonoscopy revealed a rectal tumor 2 cm
or less in diameter, which was diagnosed by biopsy as
a tubular adenocarcinoma. The other primary site of
cervicomediastinal LN carcinoma could not be determined
on whole-body CT, upper gastrointestinal endoscopy,















Figure 1 The levels of carcinoembryonic antigen (CEA) and carbohyd
the course of treatment.from infradiaphragmatic malignancies to cervicomediast-
inal LNs is rare, it was possible that the cervicomediastinal
LN carcinoma had metastasized from rectal cancer.
Biopsy specimens from the mediastinal LNs and left
supraculavicular LNs were obtained by endobronchial
ultrasound-guided transbronchial needle aspiration biopsy
and echo-guided needle aspiration biopsy, respectively,
but did not lead to a diagnosis. To identify the primary
lesion for the mediastinal LN carcinoma, a thoracoscopic
biopsy was performed in February 2009. The biopsy
specimen from the paraaortic LNs demonstrated papillary
adenocarcinoma that was pathologically different from
rectal cancer (Figure 3). Additionally, immunohistochem-
istry (IHC) studies showed the biopsy specimen from the
paraaortic LNs to be positive for thyroid transcription
factor-1 (TTF-1) and cytokeratin 7 (CK7), and negative
for cytokeratin 20 (CK20). These findings suggested the
presence of metastatic adenocarcinoma of the LN originat-
ing from lung cancer. Therefore, the patient was diagnosed
of mediastinal LN carcinoma from lung cancer with an
unknown primary lesion. The patient underwent low
anterior resection of the rectum for the rectal cancer, and
no abdominal LN metastasis (pMP, N0/stage I) was found.
Although we recommended concurrent radiotherapy with
systemic platinum-based chemotherapy for the cervico-
mediastinal LN carcinoma, the patient refused; therefore,
radiotherapy without chemotherapy was administrated
with a total dose of 50 Gy (2 Gy x 25 fractions). The size
of the LNs had decreased at 3 months after radiotherapy,
and the serum levels of CA19-9 and CEA had decreased
to 398.1 U/ml and 18.6 U/ml, respectively, in July 2009
(Figure 1). However, the serum levels of CA19-9 and CEA
increased to 1599.2 U/ml and 23.3 U/ml, respectively, in
August 2009 (Figure 1). CT was done again, and the result
revealed regrowth of mediastinal LNs at 4 months after
radiotherapy. Although we recommended systemic plat-

















Figure 2 Fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) images. Whole-body FDG-PET/CT
demonstrating high uptake in the left supraclavicular region, mediastinal region, and rectal lesion (arrows) (a), with maximum standardized uptake
values of 10.44 (b), 8.26 (c), and 6.43 (d), respectively.
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therapy on an outpatient basis. TS-1 was administered at
a dosage of 80 mg/day for 2 weeks, followed by a 1-week
rest, a treatment used for unresectable non-small cell lung
cancer. The serum CA19-9 level decreased to the normal
level, and the CEA level had also decreased to a normal or
only slightly elevated value (5.9 U/ml) after the third
course (Figure 1). No adverse effects were noted. After thex6
x33
Figure 3 Microscopic findings of resected mediastinal lymph nodes a
papillary adenocarcinoma that was pathologically different from the rectal
the tumor resected from the rectum was tubular adenocarcinoma.end of the fourth course, CT revealed a marked decrease
in the LN size and a complete response was achieved. The
cervicomediastinal lesions showed a complete biologic
response to TS-1 treatment after 12 courses as determined
by PET/CT (Figure 4). The maximum standardized uptake
value in the lesions in left supraclavicular region and
Botallo’s ligament were 2.32 and 2.26, respectively. The
serum levels of CA19-9 and CEA were maintainedx6
x33 a b
nd the rectal tumor. (a) A biopsy of the paraaortic LNs revealed
lesion (hematoxylin and eosin stain). (b) The pathological diagnosis of
ab
Figure 4 Fluorodeoxyglucose (FDG)-positron emission
tomography (PET)/computed tomography (CT) images at 12
months after TS-1 treatment. FDG-PET/CT demonstrating in the
FDG uptake of the left supraclavicular and Botallo’s ligament region,
with maximum standardized uptake values of 2.32 (arrows) (a) and
2.26 (arrows) (b), respectively.
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after TS-1 treatment (Figure 1). The patient continued
treatment with oral TS-1 without adverse events and is
currently alive without recurrence or identification of the
primary site at the 32nd month after TS-1 treatment.
Mediastinal LN carcinoma with an unknown primary
site is rare and comprises 1.5% of all cancers with un-
known primary sites [1-3]. Seventy cases of mediastinal
LN carcinoma with an unknown primary site have been
reported in Japan [9]. There is a male preponderance,
and the overall male to female ratio is 4.4:1. The median
age at diagnosis is approximately 57.7 years (range 5-85
years). The histological type was adenocarcinoma in 41%
of patients, followed by small cell carcinoma in 19%,
large cell carcinoma in 17%, and squamous cell carcinoma
in 16%. The mean survival time of patients with medias-
tinal LN carcinoma has been reported to be 28.9–30.7
months, and the prognosis of patients with mediastinal
LN carcinoma with an unknown primary site is generally
better than that of patients with primary lung cancer with
mediastinal LN metastasis [6-9].
PET/CT is useful to determine the primary lesion for
carcinoma with an unknown primary site [14]. In the
present case, PET revealed an accumulation of FDG at
the rectal lesion, which was diagnosed by biopsy as a
tubular adenocarcinoma. Although it is possible that thecervicomediastinal LN carcinoma had metastasized from
the rectal cancer, metastasis from infradiaphragmatic
malignancies to cervicomediastinal LNs is rare and has
never been reported to occur without abdominal LNs
metastasis. A thoracoscopic biopsy of the mediastinal LNs
was performed, and a biopsy specimen from the paraaortic
LNs demonstrated papillary adenocarcinoma that was
pathologically different from rectal cancer. Moereover,
IHC studies is a useful addition to HE staining in locating
the tumor site. In particular, a pattern of positive TTF-1
and CK7 expression and negative CK20 expression is
indicative of primary lung cancer. These pathological
results suggest that rectal cancer was not the origin of
the LN metastasis; therefore, a diagnosis of mediastinal LN
carcinoma with an unknown primary site was established.
A useful treatment for mediastinal LN carcinoma with
an unknown primary site has not been established.
Several surgical procedures including LN incisional biopsy,
resection, dissection and lobectomy have been reported.
Several case reports have described the complete excision
of mediastinal LN carcinoma with a good prognosis [6-8].
Therefore, mediastinal carcinoma with an unknown
primary site should be surgically excised if complete
resection is possible. In the present case, complete
excision of all of the metastatic LNs was impossible
because supracervical LN lesions were prominent.
Several reports have demonstrated the effect of che-
moradiotherapy on mediastinal LN carcinoma with an
unknown primary site. Thoracoscopic biopsies of medi-
astinal LNs from patients with multiple LN lesions and
subsequent concurrent chemoradiotherapy have indicated
poor prognosis [9]. However, two patients with medias-
tinal LN carcinoma in multiple locations that were treated
by chemoradiotherapy were reported to be alive at 24
and 33 months after the procedure [6]. Cervicomediastinal
carcinoma with an unknown primary site was also
successfully treated by chemotherapy with a platinum-
based regimen followed by sequential radiotherapy [11].
These reports suggest that chemoradiotherapy may be
useful for some cases with mediastinal LN carcinoma
in multiple locations with an unknown primary site.
Therefore, we recommended systemic platinum-based
chemoradiotherapy to the patient, but the patient re-
fused. We then applied radiotherapy to the LNs in the
mediastinal and supraclavicular region. However, cervi-
comediastinal LNs in the present case showed regrowth
at 4 months after radiotherapy, and the serum levels of
CA19-9 and CEA increased again. There have been few
reports of carcinoma with an unknown primary site in
which TS-1 was effective [15]. Currently, TS-1 is adminis-
tered for gastric, colorectal, lung, laryngeal, pancreatic,
and biliary cancers in Japan. Because the patient desired
oral chemotherapy on an outpatient basis, TS-1 was ad-
ministered after the cervicomediastinal LN carcinoma had
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treatment, PET/CT revealed a marked decrease in LN size
and in the FDG uptake of the cervicomediastinal lesions; a
complete biological response was achieved (Figure 4). The
serum levels of CA19-9 and CEA were maintained within
almost the normal range during the 31-months after TS-1
treatment. Therefore, this regimen was considered to show
clinical efficacy. At the 32nd month after TS-1 treatment,
there was no exacerbation, and the quality of life has been
maintained. TS-1 treatment for mediastinal LN carcinoma
with an unknown primary site may be recommended as
therapeutic strategy. To our knowledge, this is the first
case report in the English-language medical literature
to describe a patient successfully treated with TS-1 alone
after the relapse of cervicomediastinal LN carcinoma with
an unknown primary site.
Conclusion
TS-1 treatment for the carcinoma with an unknown pri-
mary site may be useful in patients who are not candidates
for systemic platinum-based chemotherapy, because
TTF1+ carcinoma patients are treated like non-small
cell lung cancer patients.
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